NOVERIS HEALTH SCIENCES INC. PROVIDES CLARIFYING NEWS RELEASE REGARDING LIFE OFFERING AND OTHER DISCLOSURE

Vancouver, British Columbia, April 20, 2026 – Noveris Health Sciences Inc. (the "**Company**") (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces that, as a result of a review by the British Columbia Securities Commission (the "**BCSC**"), the Company is issuing the following press release to clarify recent disclosure included in the Company's LIFE offering document dated March 11, 2026 (the "**LIFE Offering Document**", and the offering to which it relates, the "**LIFE Offering**") and news releases dated March 13 and 18, 2026.

Following the BCSC review, the Company did not qualify for the LIFE Offering and, as a result, the Company will be relying on alternate exemptions and filing an amended Report of Exempt Distribution. The securities issued under the LIFE Offering are in the process of being cancelled and re-issued with four-month restrictive holds.

The Company wishes to clarify the following statements in its LIFE Offering Document:

- the Company has active operations and its principal asset is not cash, cash equivalents or its exchange listing;
- the principal business objectives that the Company intends to accomplish using the gross proceeds of the LIFE Offering are to advance research and development; and
- the Company conducts research and development with the use of artificial intelligence.

The Company confirms that such statements should not be relied upon and are not supported by its current stage of development. The Company further clarifies:

- Prior to the closing of the LIFE Offering, the Company was focused primarily on debt restructuring, and its other active operations had been paused due to a lack of funding. Although the Company has intellectual property including three issued patents and 13 pending patent applications (two of which are pending revival), its principal assets are cash.
- In addition to budgeting a portion of funds raised from the LIFE Offering to research and development (between $421,131 and $784,881), the Company also budgeted a substantial amount of gross proceeds (between $701,884 to $1,308,134) to working capital. These particulars are contained on page 4 of the LIFE Offering Document (see "*How will we use the available funds*?"), but the working capital allocation was not reflected on page 3 (see "*What are the business objectives that we expect to accomplish using the available funds*").
- Due to the Company's focus on debt restructuring, its research and development activities were halted, including those conducted with Applied Pharmaceutical Innovations, which were terminated in November 2024. The Company intends to resume such activities in the future.. At present, its use of artificial intelligence is restricted to publicly available resources (such as ChatGPT).

In addition, with respect to its press releases of March 13 and 18, 2026, the Company wishes to clarify the following:

- Prior to completion of the LIFE Offering, the Company had been focused on debt restructuring, while maintaining its registered intellectual property/patent portfolio. The Company does not have internal artificial intelligence resources, the Company had paused the active partnership with University of Alberta since November 2024, is not serving organizations worldwide, and is no longer working toward FDA regulatory approvals
- The Company acknowledges that certain statements contained in the LIFE Offering document and news releases, including the "About Noveris" section, may have been, exaggerated, unbalanced, or speculative, and did not present a balanced view of the Company's business and stage of development. The Company can provide no assurance that its intellectual property will result in commercially viable products or successful treatment outcomes, including a source for breakthrough treatment solutions.

The Company is committed to ensuring that all future communications provide balanced and factual information regarding its business.

NOVERIS HEALTH SCIENCES INC.

Jason Birmingham
Chief Executive Officer
Tel: +1 778-900-NVRS (6877)
Investor Relations Email: fair@noveris.health
Web: http://noveris.health

About Noveris Health Sciences Inc.

The Company is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and posttraumatic stress disorder (PTSD).